Table of Contents

1 Principles of Pharma 4.0 and Focus of the Baseline Guide 9
1.1 Introduction 9
1.2 Purpose and Scope of this Baseline Guide 10
1.3 Triggers for Pharma 4.0 11
1.4 The Pharmaceutical Industry Benefits of Pharma 4.0 13
1.5 How to Use this Guide 15

2 Digital Transformation – Pathways to Success 17
2.1 General 17
2.2 Governance 17
2.3 Define the Vision, Goals, and Priorities 18
2.4 Positioning Your Organization/Stepwise Implementation 21
2.5 Different Approaches to Execute the Transformation 22

3 Holistic Control Strategy 25
3.1 Rationale for Implementation 25
3.2 The ICH-Based Control Strategy 26
3.3 The Pharma 4.0-Based Holistic Control Strategy Definition 26

4 Quality Management in the Digital Age 33
4.1 Need and Opportunity 33
4.2 Digitalization and General Principles of Quality Management 33
4.3 Validation 4.0 37
4.4 Real Time Release Testing 39
4.5 Quality and Performance 40
4.6 New Ways of Working in Digital Quality Management – Quality 4.0 42
4.7 Quality Culture in a Digitalized Environment 48

5 The Human Element: People, Organization, and Culture 49
5.1 Introduction 49
5.2 Leadership in the Pharma 4.0 Environment 49
5.3 Organizational/Operating Model Considerations 49
5.4 Roles, Skills, and Capabilities for Pharma 4.0 50
5.5 OCM and Cultural Considerations 51

6 Navigating Regulations in a Digital World 53
6.1 Selected GMP Requirements for Electronic Data and Records 54
6.2 Guidelines, Guidances, and Concept Papers 57
6.3 Technical Standards 59
6.4 Regulatory Initiatives Related to New Technologies 59

7 Process and Data Management 63
7.1 Introduction 63
7.2 Data Use 63
7.3 Data and Processes 64

©2023 ISPE. All rights reserved.

8 Plug & Produce: Principles and Challenges 73
8.1 Introduction 73
8.2 Plug & Produce Objectives and Benefits 73
8.3 Plug & Produce Framework 76
8.4 Plug & Produce Best Practices and Recommendations 87
8.5 OT Cybersecurity Considerations for Pharma 4.0 91
8.6 Transformation from the Status Quo to the Desired Pharma 4.0 State 97

9 Engineering Design and Construction 99
9.1 General Introduction 99
9.2 Key Principles for Design and Construction for Pharma 4.0 Facilities 99
9.3 Information Technology/Operational Technology (IT/OT) 99
9.4 Infrastructure Considerations for A Facility's Design to Enable Pharma 4.0 100
9.5 Greenfield Versus Brownfield 100
9.6 Engineering Implementation Roadmap 103
9.7 Applications for Pharma 4.0 In Facilities 104
9.8 Digitalization for Critical Environments – Connecting the Building Envelope with IoT Solutions 106
9.9 Digitalization in Building Design and Construction 106

10 Technologies Enabling Digital Transformation 109
10.1 Benefits of Enabling Technologies 110
10.2 Level of Adoption of Enabling Technologies 111
10.3 Key Characteristics of a Digital Solution Composed by One or More Enabling Technologies 112
10.4 Opportunities and Challenges for Enabling Technologies in the Case Studies 114

11 Appendix 1 – Case Studies 139
11.1 Case Study Number 12: Selecting Vial Container Components Intelligently with a Modeling Platform 141
11.2 Case Study Number 22: Using MI and Trending to Detect Data Integrity Issues 143
11.3 Case Study Number 34: Predictive Production Yield, AI-Based 144
11.4 Case Study Number 109: Wearables-Enabled Operations for Maintenance Operators 147
11.5 Case Study Number 231a: AI-Assisted Rescheduling of Filling Line 149
11.6 Case Study Number 231b: AI-Assisted Predictive Calibration of Cleanroom Monitoring Sensors 151
11.7 Case Study Number 236: Pharmacovigilance Improvement with Robotic Process Automation 154
11.8 Case Study Number 237: Electronic Product Information to Eliminate the Folder Package, Blockchain-Based 155
11.9 Case Study Number 238: Optimization of a Biotech Chromatography Process – AI/ML-based 158
11.10 Case Study Number 243: Cleanroom Operator Training Based on Virtual Reality 159
11.11 Case Study Number 242: Maintenance Reporting through Speech Recognition 161
11.12 Case Study Number 246: Autonomous Mobile Robot in Grade A Lyophilization 162
11.13 Case Study Number 247: Safe, Secure and Timely Individualized Cell and Gene Therapies (ICGT) 164
11.14 Case Study Number 248: 3D Digital Product Development and Manufacturing 167
11.15 Case Study Number 249: Manufacturing Deviations Analysis with NLP 170
11.16 Case Study Number 250: Operational Excellence – A Data-Driven Approach Based on Process Mining Techniques 172
11.17 Case Study Number 251: Implementation of First-Principle Driven, Analytical Design Space Modeling for Faster Time-To-Market 175
11.18 Case Study Number 252: Standard eData Exchange Platform 178
11.19 Case Study Number 253: Revolutionizing Visual Inspection through AI 181
11.20 Case Study Number 254: Integrated, Digital Engineering with Digital Twin 183
11.21 Case Study Number 257: Flexible Line and Lean Logistics for Packaging 186
11.22 Case Study Number 308: Modular Automation for R&D Laboratories 189
11.23 Case Study Number 306: Enhanced Batch Release with Big Data and IIoT 192
11.24 Case Study Number 305: eClinical 195

©2023 ISPE. All rights reserved.

11.25 Case Study Number 310: Digitizing a Manufacturing Process to Capture Key Process Knowledge – Increasing People Capability and Reducing Human Error 197
11.26 Case Study Number 309: Real Time Release 199
11.27 Case Study Number 302: Predictive Maintenance of Isolators Using Edge Computing 201
11.28 Case Study Number 332: Building a Sustainable Asset Optimization Framework 202
11.29 Case Study Number 303: Enhanced Collaboration During Design Phase of Isolators (Design Review Thanks to VR) 204
11.30 Case Study Number 258: Optimization of a Pharmaceutical Drying Process with AI 206
11.31 Case Study Number 256: Automated Line Clearance with Image Recognition/ML/AR 208
11.32 Case Study Number 307: Digital Paperless Validation 210
11.33 Case Study Number 312: Lean, Compliant, and Digital QC Laboratory 212
11.34 Case Study Number 331: COINs, Complaints Intake Support Chat Bot 215
11.35 Case Study Number 333: Reality Capture for Virtual Collaboration Using 360 Degree Cameras 217

12 Appendix 2 – The Pharma 4.0 Operating Model – Principles 221
12.1 Pharma 4.0 Operating Model Elements 222
12.2 Pharma 4.0 Operating Model Enablers 224

13 Appendix 3 – Pharma 4.0 Maturity Assessment 225
13.1 Pharma 4.0 Maturity Assessment Overview 225
13.2 The Benefits of the Pharma 4.0 Maturity Assessment 227
13.3 Definition Pharma 4.0 Maturity and Positioning (Pharma 4.0 Versus Digital Maturity) 227
13.4 How to Use It (and Who Should Perform It) 228
13.5 Interpreting the Resulting Maturity and Setting Goals 228
13.6 Pharma 4.0 Maturity Self-Assessment Tool 229

14 Appendix 4 – Reporting Schemes 237
14.1 Reporting Scheme for Product and Process Performance 237
14.2 Reporting Scheme for Pharmaceutical Quality System and Site Performance 238
14.3 Reporting Scheme for Supply Chain Performance and Risk Management 239
14.4 Reporting Scheme for Digital Transformation Readiness (Pharma 4.0 Operating Model) 240

15 Appendix 5 – Roles and Responsibilities 241

16 Appendix 6 – References 243

17 Appendix 7 – Glossary 253
17.1 Acronyms and Abbreviations 253
17.2 Definitions 258

©2023 ISPE. All rights reserved.